MAP
FATE icon

Moody Aldrich Partners’s Fate Therapeutics FATE Stock Holding History

Moody Aldrich Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-72,304
Closed -$1.62M – 162
2022
Q3 		$1.62M Buy
+72,304
New +$2.09M 0.33% 91
2018
Q4 		– Sell
-98,993
Closed -$1.61M – 100
2018
Q3 		$1.61M Buy
98,993
+15,614
+19% +$185K 0.46% 83
2018
Q2 		$946K Buy
+83,379
New +$919K 0.34% 86

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Moody Aldrich Partners's FATE Position: Q4 2022 in Review

Moody Aldrich Partners sold out of Fate Therapeutics (FATE) in Q4 2022, closing a stake of 72,304 shares — an estimated $1.62M sold.

Moody Aldrich Partners first reported a position in FATE in Q2 2018 and held it in 3 quarters. The position peaked at $1.62M in Q3 2022. 227 funds tracked by Wall St. Rank hold FATE as of Q4 2022.

  • Moody Aldrich Partners reported no remaining Fate Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Moody Aldrich Partners sold 72,304 Fate Therapeutics shares in Q4 2022, an estimated $1.62M.
  • Moody Aldrich Partners first reported a position in Fate Therapeutics in Q2 2018 and held it in 3 quarters.
  • Moody Aldrich Partners's Fate Therapeutics position peaked at $1.62M in Q3 2022.
  • 227 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2022.

Based on Moody Aldrich Partners's 13F filing for Q4 2022, filed 24 Jan 2023.